Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel

Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.

Publication ,  Journal Article
Tchivileva, IE; Lim, PF; Smith, SB; Slade, GD; Diatchenko, L; McLean, SA; Maixner, W
Published in: Pharmacogenet Genomics
April 2010

INTRODUCTION: Three common haplotypes in the gene encoding catechol-O-methyltransferase (COMT) have been associated with pain modulation and the risk of developing chronic musculoskeletal pain, namely temporomandibular disorder (TMD). Haplotypes coding for higher enzymatic activity were correlated with lower pain perception. Rodent studies showed that COMT inhibition increases pain sensitivity through beta2/3-adrenergic receptors. We hypothesized that the nonselective beta-adrenergic antagonist propranolol will reduce clinical and experimental pain in TMD patients in a manner dependent on the individuals' COMT diplotype. METHODS: Forty Caucasian female participants meeting the Research Diagnostic Criteria for TMD were genotyped for COMT polymorphisms and completed a randomized, double-blind, placebo-controlled, two-period crossover pilot study. Each period consisted of a baseline assessment week followed by an intervention week (propranolol or placebo). Changes in clinical pain ratings, psychological status, and responses to heat and pressure stimuli between baseline and intervention weeks were compared across periods. RESULTS: The number of patients reporting a reduction in pain intensity rating was greater during propranolol treatment (P=0.014) compared with placebo. Propranolol significantly reduced a composite pain index (P=0.02) but did not decrease other clinical and experimental pain ratings. When stratified by the COMT high activity haplotype, a beneficial effect of propranolol on pain perception was noted in patients not carrying this haplotype, a diminished benefit was observed in the heterozygotes, and no benefit was noted in the homozygotes. CONCLUSION: COMT haplotypes may serve as genetic predictors of propranolol treatment outcome, identifying a subgroup of TMD patients who will benefit from propranolol therapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Pharmacogenet Genomics

DOI

EISSN

1744-6880

Publication Date

April 2010

Volume

20

Issue

4

Start / End Page

239 / 248

Location

United States

Related Subject Headings

  • Temporomandibular Joint Disorders
  • Propranolol
  • Polymorphism, Single Nucleotide
  • Pharmacology & Pharmacy
  • Pharmacogenetics
  • Pain Threshold
  • Pain
  • Humans
  • Haplotypes
  • Genotype
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tchivileva, I. E., Lim, P. F., Smith, S. B., Slade, G. D., Diatchenko, L., McLean, S. A., & Maixner, W. (2010). Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study. Pharmacogenet Genomics, 20(4), 239–248. https://doi.org/10.1097/FPC.0b013e328337f9ab
Tchivileva, Inna E., Pei Feng Lim, Shad B. Smith, Gary D. Slade, Luda Diatchenko, Samuel A. McLean, and William Maixner. “Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.Pharmacogenet Genomics 20, no. 4 (April 2010): 239–48. https://doi.org/10.1097/FPC.0b013e328337f9ab.
Tchivileva, Inna E., et al. “Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.Pharmacogenet Genomics, vol. 20, no. 4, Apr. 2010, pp. 239–48. Pubmed, doi:10.1097/FPC.0b013e328337f9ab.
Tchivileva IE, Lim PF, Smith SB, Slade GD, Diatchenko L, McLean SA, Maixner W. Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study. Pharmacogenet Genomics. 2010 Apr;20(4):239–248.

Published In

Pharmacogenet Genomics

DOI

EISSN

1744-6880

Publication Date

April 2010

Volume

20

Issue

4

Start / End Page

239 / 248

Location

United States

Related Subject Headings

  • Temporomandibular Joint Disorders
  • Propranolol
  • Polymorphism, Single Nucleotide
  • Pharmacology & Pharmacy
  • Pharmacogenetics
  • Pain Threshold
  • Pain
  • Humans
  • Haplotypes
  • Genotype